Document:

Exhibit 10.1

Exhibit 10.1

TRANSDEL PHARMACEUTICALS, INC.

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (the “Agreement”) is made effective as of October 18, 2010 (the
“Effective Date”), by and between Transdel Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), and Dr. John Bonfiglio (“Executive”):

WHEREAS, The Company and the Executive desire to enter into this Agreement to provide for
Executive’s employment by the Company, upon the terms and conditions set forth herein.

The parties hereby agree as follows:

1. Duties.

1.1 Position. Executive shall serve as the Company’s Chief Executive Officer and President,
and serve as a director on the Company’s Board of Directors (the “Board”), and shall have the
duties and responsibilities incident to such position and such other duties as may be determined in
consultation with the Board. Executive shall perform faithfully, cooperatively and diligently all
of his job duties and responsibilities and agrees to and shall devote his full time, attention and
effort to the business of the Company and other assignments as directed by the Board. The
Executive will report directly to the Board.

1.2 Best Efforts. Executive will expend his best efforts on behalf of the Company in
connection with his employment and will abide by all policies and decisions made by Board, as well
as all applicable federal, state and local laws, regulations or ordinances.

1.3 Start Date. Executive agrees that he will report to work at the Company’s headquarters on
October 20, 2010 (the “Start Date”). For purposes of clarity, the Start Date will be used to
calculate Executive’s compensation and benefits pursuant to Sections 3 through 7 of this Agreement.

2. At-Will Employment. Executive’s employment with the Company is not for a specific term and
can be terminated by Executive or the Company at any time and for any reason, with or without cause
or advanced notice. The at-will nature of Executive’s employment described in this Agreement shall
constitute the entire agreement between Executive and the Company concerning the nature and
duration of Executive’s employment and the circumstance under which Executive or the Company may
terminate the employment relationship. No oral statement by any person can change the at-will
nature of Executive’s employment with the Company. If Executive shall cease serving as the
Company’s Chief Executive Officer, Executive agrees to simultaneously submit his resignation from
the Board. In addition, Executive agrees to continue to abide by the Company’s Information and
Inventions Agreement following his resignation or the termination of his employment with the
Company.

 

 

 

3. Compensation.

3.1 Annual Base Salary. As compensation for Executive’s performance of his duties hereunder,
the Company shall pay to Executive an initial base annual salary of One Hundred Fifty Thousand
Dollars ($150,000), starting on the Start Date (“Annual Base Salary”), payable in accordance with
the normal payroll practices of Company, less required deductions for state and federal withholding
tax, social security and all other employment taxes and payroll deductions.

3.2 Annual Bonus. The Executive shall be eligible to receive an annual cash bonus in an
amount up to 40% of his Annual Base Salary (the “Annual Bonus”) beginning in fiscal 2011. The
actual amount of the Annual Bonus will be determined by the Board based on Executive’s achieving
Company and personal goals established and mutually agreed upon between the Executive and the Board
of Directors. Both the goals for the Company and the Executive shall be agreed to by Executive and
the Board of Directors as follows: (i) for the remainder of fiscal year 2010, on or before
November 15, 2010; and (ii) for fiscal year 2011, on or before January 31, 2011; and (iii) for each
fiscal year thereafter, on or before January 31 for that particular year. In addition, the Board
of Directors and the Executive hereby agree that the objectives for the other officers or employees
will be determined on the same dates as set forth above. If awarded, the Annual Bonus will be paid
on or before March 15 of the year following the year in which the Annual Bonus was earned.

3.3 Salary Increase and Special Bonus. Immediately upon the date that (i) the Company closes
a debt or equity financing in which the gross proceeds to the Company equals or exceeds $ 3
million; or (ii) completes a corporate partnership transaction that includes gross proceeds to the
Company of at least $3 million to support the Company’s general and administrative expenses (each a
“Qualified Transaction”), the Executive’s Annual Base Salary shall be increased to Three Hundred
and Fifteen Thousand Dollars ($315,000). In addition, upon the closing of a Qualified Transaction,
the Company will pay Executive a bonus equal to the product of (i) $165,000 times (ii) the number
of days between the Start Date and the closing of a Qualified Transaction dividend by 365 days (the
“Special Bonus”).

3.4 Equity Grants. Subject to approval of the Board of Directors, the Executive shall be
eligible to receive a stock option grant for 400,000 shares of common stock and 50,000 shares of
restricted common stock in accordance with Transdel’s 2007 Incentive Stock and Awards Plan. For
these initial grants of stock options and restricted common stock, they will vest as follows: 25%
of the option shares and the restricted stock shall vest immediately upon the Start Date, with the
balance of the option shares and the restricted stock vesting in equal monthly installments over
the next 36 months beginning 30 days after the Start Date; provided, however, the Executive shall
gain a vested interest in an additional 10% of the option shares and the restricted stock upon the
closing of a Qualified Transaction. The exercise price of the stock option will be the reported
closing price of the Company’s common stock on the date of grant. The vesting of all options will
fully accelerate upon an Involuntary Termination of Executive’s employment within twelve months
following a Change of Control (as such terms are defined in Executive’s Option Agreement).

 

 

 

3.5 Additional Equity Grant. Contingent upon the closing of a Contingent Financing with (i)
any entity that is not listed in Exhibit A, attached hereto and incorporated herein by reference,
or (ii) any entity that is introduced to the Company by Executive after the Start Date, the Company
will issue Executive an option to purchase 200,000 shares of common stock, with 25% of the option
shares vested on the date of grant and the balance vesting in equal monthly installments over the
next 36 months. The exercise price of this option will be the reported closing price of the
Company’s common stock on the date of grant, which will take place following the public
announcement of such Qualified Transaction.

3.6 Future Equity Grants. In addition, in connection with setting the Executive’s annual
compensation, the Board will agree to examine the Executive’s overall annual compensation package
and issue an appropriate stock option grant or other equity award based on the Company’s comparator
group.

4. Health and Welfare Benefit Plans. The Company will provide to Executive and his family
throughout the term of this Agreement health, dental and vision and other benefits on the same or
substantially similar terms as those provided to Executive and the other executive officers of the
Company during the first six months of Executive’s employment with the Company.

5. Customary Benefits. Executive shall be entitled to all customary and usual fringe benefits
and shall be entitled to participate in all savings and retirement plans, practices, policies and
programs generally applicable to employees of the Company that are in effect during the Employment
Term, subject to the terms and conditions of Company’s benefit
plan documents, as applicable.

6. Business Expenses. Executive shall be entitled to receive prompt reimbursement for all
reasonable, out of- pocket business expenses incurred in the performance of his duties on behalf of
Company (including, but not limited to, cell phone, computer and internet expenses). In addition,
Executive shall be entitled to receive prompt reimbursement for all reasonable travel and lodging
expenses related to providing services at the Company’s headquarters, with all business expense
plans (i.e., how many flights back and forth per month) and amounts to be pre-approved by the
Board.

7. Vacation. Executive shall be entitled to paid vacation, personal and sick days each
calendar year, in accordance with the Company’s plans, policies and programs then in effect.
Initially Executive will be granted four (4) weeks of paid vacation, with the Executive’s vacation
for 2010 pro-rated based on the period of his service during 2010.

8. Relocation Expenses. Contingent upon the closing of a Qualified Transaction, the Company
agrees to reimburse Executive for up to $30,000 in relocation expenses associated with Executive’s
relocation to San Diego County; provided, however, that Executive shall promptly repay the Company
for any reimbursement payments made by the Company to Executive should Executive terminate his
employment from the Company for other than Good Reason (as such term is defined in Executive’s
Option Agreement) within 12 months of the Start Date.

 

 

 

9. Indemnification. In connection with the execution of the Agreement, the Company will also
enter into a customary indemnification agreement with Executive.

10. Severance Benefits. Executive and the Board recognize the fact that the Company at the
time of this Agreement, does not have the financial capacity to offer a full typical Chief
Executive Officer severance package. However, upon the closing of a Qualified Transaction, a
severance package of at least one year’s pay and continued company paid healthcare expenses will
automatically be instituted.

11. Section 409A of the U.S. Internal Revenue Code. The Company and Executive intend in good
faith that this Agreement comply with the applicable requirements of Section 409A of the Internal
Revenue Code of 1986 and that this Agreement be construed, interpreted and administered in
accordance with such intent.

12. Dispute Resolution. In the event of any dispute or claim relating to or arising out of
Executive’s employment relationship with Company, this agreement, or the termination of Executive’s
employment with Company for any reason (including, but not limited to, any claims of breach of
contract, defamation, wrongful termination or age, sex, sexual orientation, race, color, national
origin, ancestry, marital status, religious creed, physical or mental disability or medical
condition or other discrimination, retaliation or harassment), Executive and Company agree that all
disputes shall be fully resolved by confidential, binding arbitration conducted by a single neutral
arbitrator in San Diego, California through the American Arbitration Association (“AAA”) pursuant
to the AAA’s Employment Arbitration Rules, which are available at the AAA’s website at www.adr.org
or by requesting a copy from the President of the Company. The arbitrator shall permit adequate
discovery and is empowered to award all remedies otherwise available in a court of competent
jurisdiction and any judgment rendered by the arbitrator may be entered by any court of competent
jurisdiction. The arbitrator shall issue an award in writing and state the essential findings and
conclusions on which the award is based. To the fullest extent permitted by applicable law, by
signing this letter, Executive and Company both waive the rights to have any disputes or claims
tried before a judge or jury.

13. General Provisions.

13.1 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of
the parties hereto and their heirs, personal representatives and successors, including any
successor of the company by reason of any dissolution, merger, consolidation, sale of assets or
other reorganization of the Company.

13.2 Waiver. The rights and remedies of the parties to this Agreement are cumulative and not
alternative. Neither the failure nor any delay by any party in exercising any right, power or
privilege under this Agreement or the documents referred to in this Agreement will operate as a
waiver of such right, power or privilege; and no single or partial exercise of any such right,
power or privilege will preclude any other or further exercise of such right, power or privilege or
the exercise of any other right, power or privilege. To the maximum extent permitted by applicable
law, (i) no claim or right arising out of this Agreement or the documents referred to in this
Agreement can be discharged by one party, in whole or in part, by a waiver or
renunciation of the claim or right unless in writing signed by the other party; (ii) no waiver that
may be given by a party will be applicable except in the specific instance for which it is given;
and (iii) no notice to or demand on one party will be deemed to be a waiver of any obligation of
such party or of the right of the party giving such notice or demand to take further action without
notice or demand as provided in this Agreement or the documents referred to in this Agreement.

 

 

 

13.3 Validity. The invalidity or unenforceability of any provision or provisions of this
Agreement shall not affect the validity or enforceability of any other provision of this Agreement,
which shall remain in full force and effect.

13.4 Headings. The headings set forth in this Agreement are for convenience only and shall not
be used in interpreting this Agreement.

13.5 Governing Law. This Agreement will be governed by and construed in accordance with the
laws of the United States and the State of California, without reference to its conflicts of laws
principles.

13.6 Counterparts. This Agreement may be executed in one or more counterparts, all of which
when fully executed and delivered by all parties hereto and taken together shall constitute a
single agreement, binding against each of the parties.

13.7 Survival. Sections 8, 9, 10, 11 and, 12 of this Agreement shall survive Executive’s
employment by Company.

13.8 Notices. All notices, consents, waivers and other communications under this Agreement
shall be in writing and will be deemed to have been duly given when (i) delivered by hand (with
written confirmation of receipt); (ii) sent by facsimile (with written confirmation of receipt); or
(iii) when received by the addressee, if sent by a nationally recognized overnight delivery
service, return

If to Executive:

John Bonfiglio

125 Edgewood Drive

Durham, NC 27713

If to the Company:

Dr. Jeffrey Abrams

Transdel Pharmaceuticals, Inc.

4275 Executive Square, Suite 230

La Jolla, CA 92037

or to such other address as either party shall have furnished to the other in writing in accordance
herewith.

[Remainder of Page Intentionally Left Blank]

 

 

 

IN WITNESS WHEREOF, THE PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT AND FULLY
UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN.

	 	 	 	 	 	 	 
	EXECUTIVE
	 
	 	 	 	 	 	 
	/s/ John Bonfiglio	 	 
	 	 	 
	John Bonfiglio	 	 
	 
	 	 	 	 	 	 
	TRANSDEL PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	By:	 	/s/ Jeffrey Abrams	 	 
	 	 	 	 	 
	 

	 	Name:
	 	Dr. Jeffrey Abrams	 	 
	 

	 	Title:
	 	Chairman of the Board	 	 

[Signature Page to Employment Agreement]Exhibit 10.2

Exhibit 10.2

TRANSDEL PHARMACEUTICALS, INC.

2007 INCENTIVE STOCK AND AWARD PLAN

NONQUALIFIED STOCK OPTION AGREEMENT

This NONQUALIFIED STOCK OPTION AGREEMENT (the “Option Agreement”), dated as of the
20th day of October, 2010 (the “Grant Date”), is between Transdel Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), and Dr. John Bonfiglio (the “Optionee”), the Chief
Executive Officer and a director of the Company , pursuant to the Transdel Pharmaceuticals, Inc.
2007 Incentive Stock and Awards Plan (the “Plan”). Defined terms not explicitly defined in this
Nonqualified Stock Option Agreement but defined in the Plan shall have the same definitions as in
the Plan.

WHEREAS, the Company desires to give the Optionee the opportunity to purchase shares of common
stock of the Company, par value $0.001 (“Common Shares”) in accordance with the provisions of the
Plan, a copy of which is attached hereto;

NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other
good and valuable consideration, the parties hereto, intending to be legally bound hereby, agree as
follows:

1. Grant of Option. The Company hereby grants to the Optionee the right and option
(the “Option”) to purchase all or any part of an aggregate of 400,000 Common Shares. The Option is
in all respects limited and conditioned as hereinafter provided, and is subject in all respects to
the terms and conditions of the Plan now in effect and as it may be amended from time to time (but
only to the extent that such amendments apply to outstanding options). Such terms and conditions
are incorporated herein by reference, made a part hereof, and shall control in the event of any
conflict with any other terms of this Option Agreement. The Option granted hereunder is intended
to be a nonqualified stock option (“NQSO”) and not an incentive stock option (“ISO”) as
such term is defined in section 422 of the Internal Revenue Code of 1986, as amended (the “Code”).

2. Exercise Price. The exercise price of the Common Shares covered by this Option
shall be $0.80 per share. It is the determination of the committee administering the Plan (the
“Committee”) that on the Grant Date the exercise price was not less than the greater of (i) 100% of
the “Fair Market Value” (as defined in the Plan) of a Common Share, or (ii) the par value of a
Common Share.

3. Term. Unless earlier terminated pursuant to any provision of the Plan or of this
Option Agreement, this Option shall expire ten years from Grant Date (the “Expiration Date”). This
Option shall not be exercisable on or after the Expiration Date.

 

 

 

4. Exercise of Option. The Optionee shall have the right to purchase from the
Company, on and after the following dates, the following number of Common Shares, provided the
Optionee has not terminated his or her service as of the applicable vesting date:

(a) 25% of the Common Shares shall vest immediately upon October 20, 2010; and

(b) the balance of the Common Shares shall vest in equal monthly installments over the next 36
months beginning 30 days after October 20, 2010;

(c) provided, however, that Optionee shall gain a vested interest in an additional 10% of the
Common Shares upon the closing of a Qualified Transaction.

A “Qualified Transaction” shall mean (i) a debt or equity financing in which the gross proceeds to
the Company equals or exceeds $3 million; or (ii) a corporate partnership transaction that includes
gross proceeds to the Company of at least $3 million to support the Company’s general and
administrative expenses.

The Committee may accelerate any exercise date of the Option, in its discretion, if it deems such
acceleration to be desirable. Once the Option becomes exercisable, it will remain exercisable
until it is exercised or until it terminates.

5. Method of Exercising Option. Subject to the terms and conditions of this Option
Agreement and the Plan, the Option may be exercised by written notice to the Company at its
principal office. The form of such notice is attached hereto and shall state the election to
exercise the Option and the number of whole shares with respect to which it is being exercised;
shall be signed by the person or persons so exercising the Option; and shall be accompanied by
payment of the full exercise price of such shares. Only full shares will be issued.

The exercise price shall be paid to the Company —

(a) in cash, or by certified check, bank draft, or postal or express money order;

(b) through the delivery of Common Shares;

(c) by delivering a properly executed notice of exercise of the Option to the Company and a
broker, with irrevocable instructions to the broker promptly to deliver to the Company the amount
necessary to pay the exercise price of the Option;

(d) in Common Shares newly acquired by the Optionee upon the exercise of the Option; or

 

 

 

(e) in any combination of (a), (b), (c), or (d) above.

In the event the exercise price is paid, in whole or in part, with Common Shares, the portion of
the exercise price so paid shall be equal to the Fair Market Value of the Common Shares surrendered
on the date of exercise.

Upon receipt of notice of exercise and payment, the Company shall deliver a certificate or
certificates representing the Common Shares with respect to which the Option is so exercised. The
Optionee shall obtain the rights of a shareholder upon receipt of a certificate(s) representing
such Common Shares.

Such certificate(s) shall be registered in the name of the person so exercising the Option
(or, if the Option is exercised by the Optionee and if the Optionee so requests in the notice
exercising the Option, shall be registered in the name of the Optionee and the Optionee’s spouse,
jointly, with right of survivorship) and shall be delivered as provided above to, or upon the
written order of, the person exercising the Option. In the event the Option is exercised by any
person or persons after the death or disability (as determined in accordance with section 22(e)(3)
of the Code) of the Optionee, the notice shall be accompanied by appropriate proof of the right of
such person or persons to exercise the Option. All Common Shares that are purchased upon exercise
of the Option as provided herein shall be fully paid and non-assessable.

Upon exercise of the Option, Optionee shall be responsible for all employment and income taxes
then or thereafter due (whether Federal, State or local), and if the Optionee does not remit to the
Company sufficient cash (or, with the consent of the Committee, Common Shares to satisfy all
applicable withholding requirements, the Company shall be entitled to satisfy any withholding
requirements for any such tax by disposing of Common Shares at exercise, withholding cash from
Optionee’s salary or other compensation or such other means as the Committee considers appropriate
to the fullest extent permitted by applicable law. Nothing in the preceding sentence shall impair
or limit the Company’s rights with respect to satisfying withholding obligations under Section 10
of the Plan.

6. Transferability of Option. This Option is not assignable or transferable, in whole
or in part, by the Optionee other than by will or by the laws of descent and distribution. During
the lifetime of the Optionee, the Option shall be exercisable only by the Optionee or, in the event
of his or her disability, by his or her guardian or legal representative.

7. Termination of Service by Optionee. If the Optionee’s service with the Company is
terminated by the Optionee for any reason other than death or disability prior to the Expiration
Date, this Option may be exercised, to the extent of the number of Common Shares with respect to
which the Optionee could have exercised it on the date of such termination of service by the
Optionee at any time prior to the earlier of (i) the Expiration Date or (ii) ninety (90) days after
the date of such termination of service. The Plan provides for this period as a default. The
Committee may provide for different exercise periods in any particular NQSO. Any part of the Option that was not exercisable immediately before the Optionee’s termination
of service shall terminate at that time.

 

 

 

8. Disability. If the Optionee becomes disabled (as determined in accordance with
section 22(e)(3) of the Code) during his or her service and, prior to the Expiration Date, the
Optionee’s service is terminated as a consequence of such disability, this Option may be exercised,
to the extent of the number of Common Shares with respect to which the Optionee could have
exercised it on the date of such termination of service by the Optionee or by the optionee’s legal
representative, at any time prior to the earlier of (i) the Expiration Date or (ii) one year after
such termination of service. Any part of the Option that was not exercisable immediately before
the Optionee’s termination of service shall terminate at that time.

9. Termination of Service by Company without Cause or by Optionee with Good Reason.
If the Optionee’s service with the Company is terminated by the Company for any reason other than
Cause (or is terminated by the Optionee for Good Reason) prior to the Expiration Date, this Option
may be exercised, to the extent of the number of Common Shares with respect to which the Optionee
could have exercised it on the date of such termination of employment by the Optionee at any time
prior to the earlier of (i) the Expiration Date, or (ii) one year after such termination of
service. Any part of the Option that was not exercisable immediately before the Optionee’s
termination of employment shall terminate at that time.

10. Death. If the Optionee dies during his or her service and prior to the Expiration
Date, or if the Optionee’s service is terminated for any reason (as described in Paragraphs 7, 8
and 9) and the Optionee dies following his or her termination of service but prior to the earlier
of the Expiration Date or the expiration of the period determined under Paragraph 7, 8 or 9 (as
applicable to the Optionee), this Option may be exercised, to the extent of the number of Common
Shares with respect to which the Optionee could have exercised it on the date of his or her death
by the Optionee’s estate, personal representative or beneficiary who acquired the right to exercise
this Option by bequest or inheritance or by reason of the Optionee’s death, at any time prior to
the earlier of (i) the Expiration Date or (ii) one year after the date of the Optionee’s death.
Any part of the Option that was not exercisable immediately before the Optionee’s death shall
terminate at that time.

11. Termination for Cause. If the Optionee is removed by the Company for Cause and
his or her service with the Company is terminated prior to the Expiration Date, any unexercised
portion of this Option shall immediately terminate at that time.

12. Change of Control. To the extent the Option is, in connection with a Change of
Control, assumed by the acquirer in accordance with the Plan, none of the Common Shares shall vest
on an accelerated basis upon the occurrence of the Change of Control, and Optionee shall
accordingly continue, over his period of employment following the Change of Control, to vest in the
Option Shares in one or more installments in accordance with the provisions of the Option
Agreement. However, upon an Involuntary Termination of Optionee’s employment within twelve (12)
months following a Change of Control, all of the Common Shares at the time subject to the Option
shall automatically vest in full on an accelerated basis so
that the Option shall immediately become exercisable for all the Common Shares as fully-vested
shares and may be exercised for any or all of those Option Shares as vested shares. The Option
shall remain so exercisable until the earlier of (i) the Expiration Date or (ii) the expiration of
a one year period measured from the date of the Involuntary Termination.

 

 

 

For purposes of this Option Agreement,

(a) “Cause” shall mean Optionee’s: (i) acts of theft, embezzlement, fraud, material dishonesty
or misappropriation of any of the Company’s (or a surviving entity’s following a Change of Control)
property, or conviction for, or the entry of a plea of guilty or nolo contendere to, any felony, or
to any other crime involving dishonesty, moral turpitude, fraud or embezzlement; (ii) breach of
Company’s confidentiality agreement, which shall not be subject to any cure; (iii) breach of any
material provision of any written agreement between Optionee and the Company (or the surviving
entity following a Change of Control), other than a breach as described in subsection (ii) above,
and failure of Optionee to cure such beach, if susceptible to cure, within ten (10) days following
Optionee’s receipt of written notice of such breach; (iv) failure or refusal to perform, or
material negligence in the performance of, duties to the Company (or the surviving entity following
a Change of Control), or refusal or failure to follow or carry out any reasonable direction of the
board of directors of the Company (or of the applicable supervisory personnel of the surviving
entity following a Change of Control), which failure or refusal, if susceptible to cure, remains
uncured or continues or recurs after ten (10) days following Optionee’s receipt of written notice
specifying the nature of such failure or refusal; (v) inability to perform the essential functions
of Optionee’s position, with or without reasonable accommodation, due to a mental or physical
disability; or (vi) death.

(b) “Change of Control” shall mean the occurrence of any of the following: (i) the sale,
lease, conveyance or other disposition of all or substantially all of the Company’s assets to any
“person” (as such term is used in Section 13(d) of the Exchange Act of 1934, as amended), entity or
group of persons acting in concert; (ii) any person or group of persons becoming the “beneficial
owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of
the Company representing 50% or more of the total voting power represented by the Company’s then
outstanding voting securities; (iii) a merger, consolidation or other transaction of the Company
with or into any other corporation, entity or person, other than a transaction in which the holders
of at least 50% of the shares of capital stock of the Company outstanding immediately prior thereto
continue to hold (either by voting securities remaining outstanding or by their being converted
into voting securities of the surviving entity or its controlling entity) at least 50% of the total
voting power represented by the voting securities of the Company or such surviving entity (or its
controlling entity) outstanding immediately after such transaction; or (iv) a contest for the
election or removal of members of the Board of Directors of the Company that results in the removal
from the Board of at least 50% of the incumbent members of the Board; provided, however, in no
event shall the securities issued by the Company in connection with a financing transaction (i.e., the primary
purpose of which is to raise funds to support the Company’s operations) shall be deemed to be a
Change of Control.

 

 

 

(c) “Good Reason” shall mean Optionee’s resignation within sixty (60) days after the
occurrence of any of the following events without Optionee’s consent: (i) a material reduction in
the aggregate level of Optionee’s base salary and incentive compensation opportunity (other than
Company-wide reductions or reductions generally applicable to positions of comparable management
authority within the surviving entity following a Change of Control); (ii) a material reduction of
Optionee’s duties, responsibilities and requirements so that Optionee’s duties are no longer
consistent with Optionee’s position immediately prior to a Change of Control; or (iii) relocation
of Optionee’s primary place of employment by the Company (or the surviving entity following a
Change of Control) to a facility or location more than fifty (50) miles from Optionee’s primary
place of employment immediately prior to the Change in Control.

(d) an “Involuntary Termination” shall mean (i) the termination of Optionee’s employment by
the Company (or the surviving entity following a Change of Control) for reasons other than for
Cause or (ii) Optionee’s resignation for Good Reason, as those terms are defined herein.

13. Securities Matters.

(a) If, at any time, counsel to the Company shall determine that the listing, registration or
qualification of the Common Shares subject to the Option upon any securities exchange or under any
state or federal law, or the consent or approval of any governmental or regulatory body, or that
the disclosure of non-public information or the satisfaction of any other condition is necessary as
a condition of, or in connection with, the issuance or purchase of Common Shares hereunder, such
Option may not be exercised, in whole or in part, unless such listing, registration, qualification,
consent or approval, or satisfaction of such condition shall have been effected or obtained on
conditions acceptable to the Board of Directors. The Company shall be under no obligation to apply
for or to obtain such listing, registration or qualification, or to satisfy such condition. The
Committee shall inform the Optionee in writing of any decision to defer or prohibit the exercise of
an Option. During the period that the effectiveness of the exercise of an Option has been deferred
or prohibited, the Optionee may, by written notice, withdraw the Optionee’s decision to exercise
and obtain a refund of any amount paid with respect thereto.

(b) The Company may require: (i) the Optionee (or any other person exercising the Option in
the case of the Optionee’s death or Disability) as a condition of exercising the Option, to give
written assurances, in substance and form satisfactory to the Company, to the effect that such
person is acquiring the Common Shares subject to the Option for his or her own account for

 

 

 

investment and not with any present intention of selling or
otherwise distributing the same, and to make such other representations or covenants; and (ii) that
any certificates for Common Shares delivered in connection with the exercise of the Option bear
such legends, in each case as the Company deems necessary or appropriate, in order to comply with
federal and applicable state securities laws, to comply with covenants or representations made by
the Company in connection with any public offering of its Common Shares or otherwise. The Optionee
specifically understands and agrees that the Common Shares, if and when issued upon exercise of the
Option, may be “restricted securities,” as that term is defined in Rule 144 under the Securities
Act of 1933 and, accordingly, the Optionee may be required to hold the shares indefinitely unless
they are registered under such Securities Act of 1933, as amended, or an exemption from such
registration is available.

(c) The Optionee shall have no rights as a shareholder with respect to any Common Shares
covered by the Option (including, without limitation, any rights to receive dividends or non-cash
distributions with respect to such shares) until the date of issue of a stock certificate to the
Optionee for such Common Shares. No adjustment shall be made for dividends or other rights for
which the record date is prior to the date such stock certificate is issued.

14. Governing Law. This Option Agreement shall be governed by the applicable Code
provisions to the maximum extent possible. Otherwise, the laws of the State of Delaware (without
reference to the principles of conflict of laws) shall govern the operation of, and the rights of
the Optionee under, the Plan and Options granted thereunder.

IN WITNESS WHEREOF, the Company has caused this Nonqualified Stock Option Agreement to be duly
executed by its duly authorized officer, and the Optionee has hereunto set his or her hand and
seal, all as of the 20th day of October, 2010.

	 	 	 	 	 
	 	Transdel Pharmaceuticals, Inc.

 	 
	 	By:  	/s/ John Lomoro
 	 
	 	 	     Name:  	John Lomoro 	 
	 	 	     Title:  	Chief Financial Officer 	 
	 
	 	 	 
	 	         /s/ John Bonfiglio
 	 
	 	             Optionee:  John Bonfiglio, Ph.D. 	 
	 	 	 

 

 

 

	 	 	 	 	 

TRANSDEL PHARMACEUTICALS, INC.

2007 INCENTIVE STOCK AND AWARDS PLAN

Notice of Exercise of Nonqualified Stock Option

I hereby exercise the nonqualified stock option granted to me pursuant to the Nonqualified
Stock Option Agreement dated as of October 20, 2010 by Transdel Pharmaceuticals, Inc. (the
“Company”), with respect to the following number of shares of the Company’s common stock
(“Shares”), par value $0.001 per Share, covered by said option:

	 	 	 	 	 	 	 	 	 

	 

	 	Number of Shares to be purchased:	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	Purchase price per Share:
	 	 	$	 	 	 
	 

	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	Total purchase price:
	 	 	$	 	 	 
	 

	 	 	 	 	 	 	 

	 	 	 	 	 

	—

	 	A.
	 	Enclosed is cash or my certified
check, bank draft, or postal or express money order in the amount of
$________
in full/partial [circle one] payment for such Shares;

and/or

	 	 	 	 	 

	—

	 	B.
	 	Enclosed is/are _____ Share(s) with a total fair market value of $_____
on the date hereof in full/partial [circle one] payment for such Shares;

and/or

	 	 	 	 	 

	—

	 	C.
	 	I have provided notice
to_____[ insert name of
broker], a broker, who will render full/partial [circle one] payment for such Shares.
[Optionee should attach to the notice of exercise provided to such broker a copy of this
Notice of Exercise and irrevocable instructions to pay to the Company the full exercise
price.]

and/or

	 	 	 	 	 

	—

	 	D.
	 	I elect to satisfy the payment for Shares purchased hereunder by having the Company
withhold newly acquired Shares pursuant to the exercise of the Option.

 

 

 

Please have the certificate or certificates representing the purchased Shares registered in
the following name or names*:_______________; and sent to _____________.

	 	 	 	 	 
	 	 	 
	DATED:__________ ____, 20__ 	
 	 
	 	Optionee’s Signature 	 
	 	 	 
	 

 

*Certificates may be registered in the
name of the Optionee alone or in the joint names (with right of survivorship)
of the Optionee and his or her spouse.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]